Amplia Therapeutics (ATX) Stock Price, News & Analysis

Company Overview

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 77,249 shs
• Average Volume: N/A
• Market Capitalization: A$30.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Amplia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amplia Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:ATX
• CIK: N/A
• Web: www.ampliatx.com
• Phone: 61 2 8003 3650
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$4.50 million
• Net Margins: -101.14%
• Pretax Margin: N/A
• Return on Equity: -34.42%
• Return on Assets: -17.04%

Debt

• Debt-to-Equity Ratio: 13.89
• Current Ratio: 1.98
• Quick Ratio: 5.05

Sales & Book Value

• Annual Sales: A$4.45 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 4.88
• Book Value: A$0.06 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 274,800,000
• Free Float: N/A
• Market Cap: A$30.65 million
• Optionable: Not Optionable
• Beta: 0.72